LAB Standard BioTools Inc Company Net Income

Official company branding of Standard BioTools (LAB)

Standard BioTools Inc. (LAB) is optimizing its electronics procurement by diversifying partners outside of Asia to ensure production stability. Instrument transportation relies on strict temperature controls and protective packaging. Serving as a valuation tool, this price-to-earnings chart, which currently stands at -0.09, confirms the business's strong market position driven by its unique mass cytometry technology, which generates sustained demand for equipment.

Company Net Income: Standard BioTools Inc. (LAB) for 04/28/2023 - 10/29/2026

Analytical breakdowns and data insights for company Standard BioTools (LAB)

- market value and analyst target forecast:
Stock Price Standard BioTools Corp|LAB - Price Target Chart
- market capitalization data:
Market Value Standard BioTools Corp|LAB - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Asset Value per Share Standard BioTools|LAB - Company Book Value|Market Capitalization to Book Value fluidigm.com|LAB - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Standard BioTools Inc.|LAB - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Standard BioTools Inc|LAB - Company Debts|Debts to Net Assets Standard BioTools Corp|LAB - Company Long-Term Liabilities|Amount of Current Liabilities Standard BioTools|Quick Ratio fluidigm.com
- company profitability and valuation multiples indicators:
LAB - Company Net Income
Basic company analysis:LAB - Standard BioTools Corp
Mass-produced product of Fluidigm

Standard BioTools Inc. (LAB) ability to withstand market downturns depends directly on the effective execution of its technology merger strategy. As a manufacturer of bioanalytical equipment, the company is vulnerable to reductions in capital expenditures by biotech startups. An analysis of the company's quarterly earnings allows for an assessment of the business's aggregate market power and the stability of its operating cash flows. This metric aggregates investor expectations, reflecting the actual ability to generate net income. Positive momentum in this indicator minimizes the risk of losses and guarantees the sustainability of payments.

Key competitors

Agilent Corp (A) - Net Profit|Company Net Income Quest Diagnostics|Company Net Income ILMN|Net Income EXAS (Exact Sciences Corporation)|RVTY - Company Net Income|Company Net Income Bio-Rad Laboratories Inc BIO|Net Financial Result Anbio Corp (NNNN)|Sotera Health Company - Net Profit|Net Financial Result quidel.com QDEL|OPKO Health (OPK) - Company Net Income|CDNA - Net Financial Result|Company Net Income Maravai LifeSciences Corp|Fulgent (FLGT) - Net Financial Result|Net Income CTKB (Cytek Biosciences, Inc.)|Profit After Payment of Taxes OSUR|Net Profit XGN (Exagen)|Net Profit MDxHealth S.A. MDXH|LUCD - Company Net Income|PRE (Prenetics Global) - Company Profit|IMDX: Net Profit|Company Profit TRIB|PRPH (ProPhase Labs) - Net Profit|Net Profit Ainos Inc|Company Net Income Co-Diagnostics Corp (CODX)|HSCS (Heart Test Labs) - Final Profit|Net Profit BMRA (Biomerica, Inc.)|CDIO: Company Profit|VRAX: Net Income|Final Profit BJDX (Bluejay Diagnostics Inc)|AWH: Net Profit|AXDX (Accelerate Diagnostics Inc) - Company Net Income|CNTG (Centogene) - Net Profit|Enzo (ENZ) - Net Financial Result|Company Net Income Fresh2 Group Limited (FRES)|GENE - Company Net Income|23andMe Inc. - Net Income|Profit After Payment of Taxes PMD (Psychemedics Inc)